Collaborative Arrangement, Rights And Obligations, Aggregate Upfront Payments Due Upon Execution

No definition available.

Name:	mrk_CollaborativeArrangementRightsAndObligationsAggregateUpfrontPaymentsDueUponExecution
Namespace Prefix:	mrk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights And Obligations, Aggregate Upfront Payments Due Upon Lapse Of Time

+ References

No definition available.

+ Details

Name:	mrk_CollaborativeArrangementRightsAndObligationsAggregateUpfrontPaymentsDueUponLapseOfTime
Namespace Prefix:	mrk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights And Obligations, Liable Contracted Portion Amount Of Research And Development Expenses To Incur Costs For

+ References

No definition available.

+ Details

Name:	mrk_CollaborativeArrangementRightsAndObligationsLiableContractedPortionAmountOfResearchAndDevelopmentExpensesToIncurCostsFor
Namespace Prefix:	mrk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights And Obligations, Liable Contracted Portion Amount Of Research And Development Expenses To Incur Costs For, Percentage

+ References

No definition available.

+ Details

Name:	mrk_CollaborativeArrangementRightsAndObligationsLiableContractedPortionAmountOfResearchAndDevelopmentExpensesToIncurCostsForPercentage
Namespace Prefix:	mrk_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Milestone Payments, Per Product

+ References

No definition available.

+ Details

Name:	mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentMilestonePaymentsPerProduct
Namespace Prefix:	mrk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights And Obligations, Number Of Antibody Drug Conjugates

+ References

No definition available.

+ Details

Name:	mrk_CollaborativeArrangementRightsAndObligationsNumberOfAntibodyDrugConjugates
Namespace Prefix:	mrk_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Collaborative Arrangement, Rights And Obligations, Refundable Upfront Payments

+ References

No definition available.

+ Details

Name:	mrk_CollaborativeArrangementRightsAndObligationsRefundableUpfrontPayments
Namespace Prefix:	mrk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights And Obligations, Royalty Percentage

+ References

No definition available.

+ Details

Name:	mrk_CollaborativeArrangementRightsAndObligationsRoyaltyPercentage
Namespace Prefix:	mrk_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482916/730-10-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482517/912-730-25-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481283/985-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=mrk_DaiichiSankyoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrk_IfinatamabDeruxtecanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrk_PatritumabDeruxtecanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrk_RaludotatugDeruxtecanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mrk_PatritumabDeruxtecanAndRaludotatugDeruxtecanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative Arrangements - Daiicho Sankyo - Narrative (Details) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Mar. 31, 2023 USD ($)	Oct. 31, 2023 USD ($) candidate
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development	$ 3,992		$ 4,276
Daiichi Sankyo \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of antibody drug conjugates obtained right and obligations \| candidate				3
Aggregate upfront payments due upon execution in collaborative arrangement				$ 4,000
Refundable upfront payments in collaborative arrangement				1,000
Maximum aggregate contingent milestone payments, per product, in collaborative arrangement				$ 5,500
Research and development	$ 69	$ 5,500	$ 0
Sales based royalty percentage				5.00%
Daiichi Sankyo \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Ifinatamab Deruxtecan
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Refundable upfront payments in collaborative arrangement				$ 500
Daiichi Sankyo \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Patritumab Deruxtecan
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Refundable upfront payments in collaborative arrangement				500
Aggregate upfront payments due upon lapse of time in collaborative arrangement				750
Daiichi Sankyo \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Raludotatug Deruxtecan
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate upfront payments due upon lapse of time in collaborative arrangement				$ 750
Liable contracted portion of research and development expenses to incur costs for in collaborative arrangement, percentage				75.00%
Liable contracted portion of research and development expenses to incur costs for in collaborative arrangement				$ 2,000
Daiichi Sankyo \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Patritumab Deruxtecan And Raludotatug Deruxtecan
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate upfront payments due upon lapse of time in collaborative arrangement		$ 1,500